Race Oncology Limited
ASX:RAC Stock Report
Race Oncology Past Earnings Performance Race Oncology's earnings have been declining at an average annual rate of -27.6%, while the Biotechs industry saw earnings growing at 12.3% annually. Revenues have been growing at an average rate of 64.9% per year.
Key information
-27.6%
Earnings growth rate
Biotechs Industry Growth 9.6% Revenue growth rate 64.9% Return on equity -75.5% Net Margin -345.2% Last Earnings Update 30 Jun 2024
Recent past performance updates
Show all updates
Race Oncology Limited, Annual General Meeting, Nov 25, 2024 Oct 07
Consensus revenue estimates increase by 12% Oct 01
Is Race Oncology (ASX:RAC) In A Good Position To Deliver On Growth Plans? Aug 26
Price target increased by 26% to AU$3.22 Jun 29
New minor risk - Share price stability Jun 06
New minor risk - Shareholder dilution May 17
We Think Race Oncology (ASX:RAC) Needs To Drive Business Growth Carefully May 10
New minor risk - Shareholder dilution Mar 30
New major risk - Financial position Feb 29
We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate Jan 23
Race Oncology Limited Appoints Daniel Tillett as Chief Executive Officer Nov 22
Race Oncology Limited, Annual General Meeting, Nov 27, 2023 Oct 10
Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation Oct 05
New minor risk - Share price stability Oct 05
New minor risk - Financial data availability Aug 30
Race Oncology Limited Announces Board Changes Aug 22
New minor risk - Market cap size Aug 15
Race Oncology Limited Announces Board Changes Jun 29
Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth Jun 20
Race Oncology Limited Appoints Michelle Rashford Chief Medical Officer, Effective 1 July 2023 May 09
We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow Feb 17
Race Oncology Limited Appoints Damian Clarke-Bruce as Director Feb 02
Race Oncology Limited Receives Human Ethics Approval for Observational Cardioprotection Breast Cancer Trial Feb 01
Race Oncology Limited, Annual General Meeting, Feb 21, 2023 Jan 19
Board Member recently bought AU$50k worth of stock Jan 17
Board Member recently bought AU$99k worth of stock Dec 23 Race Oncology Limited Appoints Damian Clarke-Bruce as Managing Director, Effective 1 February 2023
Race Oncology Limited Announces It Has Submitted A Human Ethics Application to Hunter New England Human Research Ethics Committee Seeking Approval to Commence the Observational Stage of A Planned Phase 1/2B Clinical Trial of Zantrene Dec 10
Race Oncology Limited Appoints Daniel (Danny) Sharp as an Independent Non-Executive Director Dec 05
Race Oncology Limited Receives Positive Guidance on Zantrene Via Pre-IND Meeting with US FDA Nov 23
High number of new and inexperienced directors Nov 16
Race Oncology Ltd Announces Management Changes Nov 11
Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation Oct 14
Race Oncology Limited, Annual General Meeting, Nov 24, 2022 Oct 04
Race Oncology Limited Develops Improved Iv Formulation of Zantrene Sep 28
Race Oncology Limited Initiates New Drug Discovery Program Sep 27
Board Member recently bought AU$165k worth of stock Sep 27
Race Oncology Limited Shares Further Interim Results from Preclinical Cardioprotection Program in Collaboration with Researchers from the University of Newcastle Jun 30
Race Oncology Limited Announces Interim Results from its Preclinical Melanoma Research Program Jun 22
Race Oncology Limited Expands FTO Targeting Phase 1b/2a Extramedullary AML & MDS Trial to Europe Jun 09
Race Oncology Limited Announces the Dose Escalation Phase 1b Stage of the Relapsed or Refractory Acute Myeloid Leukaemia (R/R AML) Trial Running At the Chaim Sheba Medical Centre, Israel May 27
Race Oncology Limited Appoints Guy Breitenbucher to Its Scientific Advisory Board May 19
Race Oncology Limited Receives Governance Approval for AML EMD & MDS Trial May 12
High number of new and inexperienced directors Apr 27
Race Oncology Limited Receives Human Ethics Approval for Its Open Label Clinical Trial of Zantrene in Patients with Extramedullary Acute Myeloid Leukaemia or High-Risk Myelodysplastic Syndrome Apr 06
Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation Apr 01
Race Oncology Limited Announces Preclinical & Clinical Programs Update Mar 31
Board Member recently bought AU$56k worth of stock Mar 06
Race Oncology Limited Announces MD Anderson Cancer Center Collaborators Publish Peer Reviewed AML Preclinical Study on Zantrene Feb 24
Race Oncology Limited Appoints Christina Manfre as Chief Financial Officer Jan 31
Non-Independent Non-Executive Chairman recently sold AU$995k worth of stock Jan 11
Board Member recently bought AU$59k worth of stock Dec 17
Insider recently sold AU$4.4m worth of stock Nov 30
Race Oncology Limited Announces Interim Results from the Zantrene® Preclinical Heart Safety Research Program Led by Eminent Cardiotoxicity Researchers, Associate Professors Aaron Sverdlov and Doan Ngo Nov 22
Non-Independent Non-Executive Chairman exercised options to buy AU$9.8m worth of stock. Nov 14
Non-Independent Non-Executive Chairman recently bought AU$710k worth of stock Nov 08
Non-Executive Chairman recently sold AU$193k worth of stock Sep 07
Non-Executive Chairman exercised options to buy AU$5.7m worth of stock. Aug 25
Insider recently sold AU$4.3m worth of stock Aug 04
Race Oncology Limited Executes Contract to Commence Phase 1b/2 AML Trial at Chaim Sheba Israel Jun 23
Insider recently sold AU$4.8m worth of stock Apr 27
We're Hopeful That Race Oncology (ASX:RAC) Will Use Its Cash Wisely Apr 05
Insider recently sold AU$6.6m worth of stock Mar 16
Race Oncology Limited Announces Compelling Preclinical Breast Cancer Results Mar 10
Insider recently sold AU$2.1m worth of stock Mar 08
What Percentage Of Race Oncology Limited (ASX:RAC) Shares Do Insiders Own? Mar 01
New 90-day high: AU$3.29 Feb 25
Race Oncology Limited Announces Positive Early Preclinical Ovarian Cancer Results Feb 23
Professor Borje Andersson to Resign as Chief Medical Officer of Race Oncology Limited Feb 19
Race Oncology Limited Appoints Mary Harney as Non-Executive Director Feb 08
New 90-day high: AU$2.48 Feb 05
How Much Are Race Oncology Limited (ASX:RAC) Insiders Taking Off The Table? Jan 07
Race Oncology Limited Announces Borje Andersson Resigns as an Executive Director Dec 10
Race Oncology Limited Announces Breast Cancer Clinical Trial Program Initiated Nov 27
New 90-day high: AU$1.30 Nov 09
Race Oncology Limited Reports Phase II Bisantrene Trial Data to be presented at ASH 2020 Nov 06
Race Oncology Limited Announces Director Resignations Oct 29
New 90-day low: AU$0.76 Oct 06
Race Oncology Limited Appoints Borje S. Andersson as Chief Medical Officer and Executive Director Oct 02
Race Oncology Limited Appoints Phil Lynch as Chief Executive Officer Sep 03 Race Oncology Limited announced that it expects to receive AUD 3 million in funding from Merchant Funds Management Pty Ltd and other investors
Revenue & Expenses Breakdown
How Race Oncology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History ASX:RAC Revenue, expenses and earnings (AUD Millions) Date Revenue Earnings G+A Expenses R&D Expenses 30 Jun 24 4 -14 4 11 31 Mar 24 5 -12 4 11 31 Dec 23 6 -11 3 11 30 Sep 23 4 -11 3 9 30 Jun 23 3 -10 3 8 31 Mar 23 2 -10 3 7 31 Dec 22 1 -11 3 7 30 Sep 22 1 -11 4 6 30 Jun 22 1 -11 4 6 31 Mar 22 1 -10 4 5 31 Dec 21 1 -9 4 4 30 Sep 21 1 -8 4 3 30 Jun 21 0 -6 3 2 31 Mar 21 0 -5 3 2 31 Dec 20 0 -4 3 1 30 Sep 20 0 -4 2 1 30 Jun 20 0 -4 2 1 31 Mar 20 0 -3 2 1 31 Dec 19 0 -3 1 1 30 Sep 19 0 -3 1 1 30 Jun 19 0 -4 2 1 31 Mar 19 0 -4 2 1 31 Dec 18 0 -5 3 1 30 Sep 18 0 -6 4 1 30 Jun 18 0 -6 4 1 31 Mar 18 0 -6 4 1 31 Dec 17 0 -6 3 1 30 Sep 17 0 -5 3 1 30 Jun 17 0 -4 3 1 31 Mar 17 0 -3 2 1 31 Dec 16 0 -2 2 0 30 Sep 16 0 -1 1 0 30 Jun 16 0 0 0 0 31 Mar 16 0 0 0 0 31 Dec 15 0 0 0 0 30 Sep 15 0 0 0 0 30 Jun 15 0 0 0 0
Quality Earnings: RAC is currently unprofitable.
Growing Profit Margin: RAC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RAC is unprofitable, and losses have increased over the past 5 years at a rate of 27.6% per year.
Accelerating Growth: Unable to compare RAC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RAC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (2.7%).
Return on Equity
High ROE: RAC has a negative Return on Equity (-75.47%), as it is currently unprofitable.
Return on Capital Employed
Discover strong past performing companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
